Prognositic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer.

• DOI: 10.1200/jco.2011.29.15_suppl.4594
• Publication Date: 2017-02-23T18:58:03Z
• Authors: J. Sharma; C. T. Yiannoutsos; N. M. Hahn; C. Sweeney
• Keywords: Bone remodeling; N-terminal telopeptide

4594 Background: Elevated markers of bone turnover at baseline are prognostic for poorer cancer outcomes. Suppressed levels on therapy may be better ADT efficacy in controlling prostate cancer. Methods: Markers were assessed and 6 months a prospective trial patients with metastases commencing ADT. Association time to castration resistant (CRPC) skeletal related event (SRE) was evaluated using MVA model Cox regression analysis covariates treatment assignment 30 mg/day risedronate versus placebo known variables, PSA nadir < 0.2 ng/ml vs. > extent metastases. Results: Between 12/03 8/05, 63 enrolled median follow-up 39.7 months. BTO available 50 40 The values urine n-telopeptide (nmolBCE/mmol Creat) - 42.65/27.40; total DPD (nmol/mmol 9.84/8.30; specific alkaline phosphatase (ng/mL) 20.35/9.77 serum osteocalcin (μg/mL) -19.43/16.82. On MVA, month which all below the marker level (p=0.014), (p=0.042) lower volume (p=0.033), associated longer SRE. biomarkers 0.2ng/ml factors CRPC (p=0.026 p=0.058 respectively) only factor weakly OS (p=0.092) this study men metastatic involvement. Conclusions: Lower is outcomes